Last reviewed · How we verify
NCT07020884
A Study of ZT002 Injection With Subjects With Overweight or Obesity
Phase 2 trial testing ZT002 Injection in Overweight or Obesity in 303 participants. Completed in 29 May 2025.
7 May 2025
Quick facts
| Lead sponsor | Beijing QL Biopharmaceutical Co.,Ltd |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 303 |
| Start date | 14 August 2024 |
| Primary completion | 7 May 2025 |
| Estimated completion | 29 May 2025 |
| Sites | 16 locations across China |
Drugs / interventions tested
- ZT002 Injection — full drug profile →
- ZT002 Placebo
Conditions studied
- Overweight or Obesity — all drugs for Overweight or Obesity →
Sponsor
Beijing QL Biopharmaceutical Co.,Ltd — full company profile →
Who can join
Adults 18 to 75, any sex, with Overweight or Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the percentage change from baseline in weight after 24 weeks of treatment with ZT002 Injection in subjects with overweight/obesity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07020884
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of ZT002 Injection
Trials testing the same drug.
- NCT07065032 — A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM) · Phase 1, PHASE2 · completed
- NCT06371326 — A Study of ZT002 Injection in Participants With Overweight or Obesity · Phase 1 · completed
Other recruiting trials for Overweight or Obesity
Currently open trials in the same condition.
- NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
- NCT07431086 — Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US · Phase 2 · recruiting
- NCT07294235 — A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants · Phase 1 · recruiting
- NCT07224399 — Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multi · Phase 1 · recruiting
- NCT07170319 — A Study of IBI3032 in Chinese Participants With Overweight or Obesity · Phase 1 · active not recruiting
Other Beijing QL Biopharmaceutical Co.,Ltd trials
Trials by the same sponsor.
- NCT07443059 — A Study of Zovaglutide (ZT002 Injection) in Participants With Impaired Kidney Function and Healthy Participants · Phase 1 · not yet recruiting
- NCT07230119 — A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1) · Phase 3 · not yet recruiting
- NCT07184502 — Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZT003 Injection Following Single and Multiple Subcut · Phase 1 · recruiting
- NCT07307638 — Dose-escalation and Food Effect Study of ZT006 in Healthy, Overweight and Obese Participants · Phase 1 · completed
- NCT07065032 — A Study of ZT002 Injection in Adult Chinese Subjects With Type 2 Diabetes Mellitus (T2DM) · Phase 1, PHASE2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07020884 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing QL Biopharmaceutical Co.,Ltd
- Last refreshed: 10 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07020884.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing